share_log

Guggenheim Downgrades Deciphera Pharmaceuticals to Neutral

Benzinga ·  Apr 30 13:03

Guggenheim analyst Michael Schmidt downgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Buy to Neutral.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment